BRNS vs CTAS · $38.2M cap vs P/E 51, rev $11.26B
Barinthus Biotherapeutics plc (BRNS) versus Cintas Corporation (CTAS) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Latest reported BRNS revenue for 2025-09-30 was $0. Net income was -$14.6M. BRNS currently screens at market cap $38.2M.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
BRNS currently screens at market cap $38.2M. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Not investment advice. Open the BRNS and CTAS stock pages for the full models.
Not investment advice.